Last reviewed · How we verify
LY3561774
At a glance
| Generic name | LY3561774 |
|---|---|
| Also known as | Solbinsiran |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Solbinsiran (LY3561774) in Participants With Severe Hypertriglyceridemia (PHASE2)
- A Study of LY3561774 in Participants With Mixed Dyslipidemia (PHASE2)
- A Study of LY3561774 in Participants With Dyslipidemia (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3561774 CI brief — competitive landscape report
- LY3561774 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI